These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
515 related articles for article (PubMed ID: 17416870)
1. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. Lejeune FJ; Eggermont AM J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870 [No Abstract] [Full Text] [Related]
2. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS; J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537 [TBL] [Abstract][Full Text] [Related]
3. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986 [TBL] [Abstract][Full Text] [Related]
4. Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma? Garrido-Laguna I; Ponz M; Espinós J J Clin Oncol; 2007 Mar; 25(9):1149; author reply 1149-51. PubMed ID: 17369585 [No Abstract] [Full Text] [Related]
5. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor]. Kettelhack C; Hohenberger P; Schlag PM Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810 [TBL] [Abstract][Full Text] [Related]
6. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234 [TBL] [Abstract][Full Text] [Related]
7. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345 [TBL] [Abstract][Full Text] [Related]
8. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821 [TBL] [Abstract][Full Text] [Related]
10. Effective therapy: repeat limb perfusion for recurrent melanoma. Krementz ET J Am Coll Surg; 1996 Jun; 182(6):547-8. PubMed ID: 8646356 [No Abstract] [Full Text] [Related]
11. Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan. Hohenberger P; Bida B; Schlag PM Strahlenther Onkol; 1996 Nov; 172 Suppl 2():14-5. PubMed ID: 8946039 [No Abstract] [Full Text] [Related]
12. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498 [TBL] [Abstract][Full Text] [Related]
13. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis. Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758 [TBL] [Abstract][Full Text] [Related]
14. [Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs]. Abu-Abid S; Gutman M; Lev D; Inbar M; Chaitchik S; Sorkine P; Rudick V; Meller I; Klausner JM Harefuah; 1996 Oct; 131(7-8):227-32, 296, 295. PubMed ID: 8940515 [TBL] [Abstract][Full Text] [Related]
15. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma]. Kettelhack C; Hohenberger P; Schlag PM Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487 [TBL] [Abstract][Full Text] [Related]
16. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435 [TBL] [Abstract][Full Text] [Related]
17. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605 [TBL] [Abstract][Full Text] [Related]
18. Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US. Santillan AA; Zager JS Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1033-7. PubMed ID: 20078252 [No Abstract] [Full Text] [Related]
19. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Fraker DL; Alexander HR; Andrich M; Rosenberg SA Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465 [TBL] [Abstract][Full Text] [Related]